HANGZHOU (Reuters) -China’s Sciwind Biosciences is in talks with a U.S. company interested in licensing its experimental weight-loss drug for American patients, the drugmaker’s chief executive told Reuters. Overweight patients treated with Sciwind’s ecnoglutide drug lost an average of 10% to 15% of their body weight, roughly in line with results from Novo Nordisk’s top-selling obesity treatment Wegovy, according to a late-stage study published in medical journal The Lancet Diabetes & Endocrinology in June. “We also hope we are able to successfully license out, and they will apply for approval in the U.S.,” Sciwind Biosciences CEO Pan Hai said, declining to identify the firm or disclose financial terms under discussion.
